11/28/2016 10:53:45 AM
WuXi Biologics, a division of CRO/CMO WuXi AppTec, signed a non-binding MOU to create a manufacturing partnership with Australia's Prima Biomed. The partnership, if finalized, would develop Prima's recombinant soluble LAG-3 protein and other LAG-3 related products as oncology drugs. WuXi Biologics is already supplying IMP321 to Prima for clinical trials, and the new agreement would make WuXi worldwide supplier of the drug, with the exception of greater China. Eddingpharm has exclusive rights to IMP321 for greater China.
comments powered by